Stockbridge Partners’s Ginkgo Bioworks DNA Stock Holding History

Stockbridge Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$9.27M	–	20
2021 Q3	$9.27M	Buy	+20,000	New	+$9.74M	0.19%	19

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Stockbridge Partners's DNA Position: Q4 2021 in Review

Stockbridge Partners sold out of Ginkgo Bioworks (DNA) in Q4 2021, closing a stake of 20,000 shares — an estimated $9.27M sold.

Stockbridge Partners first reported a position in DNA in Q3 2021 and held it in 1 quarter. The position peaked at $9.27M in Q3 2021. 164 funds tracked by Wall St. Rank hold DNA as of Q4 2021.

Stockbridge Partners reported no remaining Ginkgo Bioworks position as of Q4 2021 after selling out during the quarter.
Stockbridge Partners sold 20,000 Ginkgo Bioworks shares in Q4 2021, an estimated $9.27M.
Stockbridge Partners first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 1 quarter.
Stockbridge Partners's Ginkgo Bioworks position peaked at $9.27M in Q3 2021.
164 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2021.

Based on Stockbridge Partners's 13F filing for Q4 2021, filed 14 Feb 2022.